Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model (original) (raw)
Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
Wright W Nichols
Antimicrobial Agents and Chemotherapy, 2012
View PDFchevron_right
Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia
Marc Tonnellier
Intensive Care Medicine, 2006
View PDFchevron_right
Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa: In Vivo and In Vitro Evidence
Nuria Campillo
Antibiotics
View PDFchevron_right
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model
María-José Giménez
Journal of Antimicrobial Chemotherapy, 2005
View PDFchevron_right
Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms ofPseudomonas aeruginosa
Wright W Nichols
Journal of Antimicrobial Chemotherapy, 2017
View PDFchevron_right
Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012–2016
Elmano Ramalheira
Diagnostic Microbiology and Infectious Disease, 2019
View PDFchevron_right
Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients
A. Vergison
The Journal of antimicrobial chemotherapy, 2015
View PDFchevron_right
Potentiation of ceftazidime by avibactam against β-lactam-resistantPseudomonas aeruginosain anin vitroinfection model
Wright W Nichols
Journal of Antimicrobial Chemotherapy
View PDFchevron_right
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh- or Lung-Infection
Wright W Nichols
Antimicrobial Agents and Chemotherapy, 2015
View PDFchevron_right
Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa
Roberto Luzzati
International journal of antimicrobial agents, 2016
View PDFchevron_right
Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response
Gilles Potel
Journal of Antimicrobial Chemotherapy, 2012
View PDFchevron_right
Ceftolozane/Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance
Bo Maung
Antimicrobial Agents and Chemotherapy, 2019
View PDFchevron_right
In vitro effect of subinhibitory concentrations of ceftazidime and meropenem on the serum sensitivity of Pseudomonas aeruginosa strains
Katarina Sakić-zdravcević, Domagoj Drenjancević, Jasmina Vranes
Collegium antropologicum, 2007
View PDFchevron_right
Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused by Pseudomonas aeruginosa
Julie Ramos
American Journal of Respiratory and Critical Care Medicine, 2011
View PDFchevron_right
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa
Wright W Nichols
Antimicrobial agents and chemotherapy, 2018
View PDFchevron_right
Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa
A. Forrest, N. Ly, William Jusko
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
Helio Sader
Journal of Antimicrobial Chemotherapy, 2014
View PDFchevron_right
In-vitro Efficacy of Ceftazidime in Combinations with Meropenem, Piperacillin/Tazobactam, Amikacin and Ciprofloxacin against Extensively Drug-Resistant Pseudomonas aeruginosa
Aamir Jamal Gondal, Waqas Latif
Pakistan journal of zoology
View PDFchevron_right
Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa
Helio Sader
Journal of Clinical Microbiology, 2018
View PDFchevron_right
Higher MICs (>2 mg/L) Predict 30-day Mortality in patients with Lower Respiratory Tract Infections Caused by Multidrug and Extensively Drug Resistant Pseudomonas aeruginosa Treated with Ceftolozane/Tazobactam
laura parraga
Open Forum Infectious Diseases
View PDFchevron_right
Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates
Nahla Eltai
Antimicrobial agents and chemotherapy, 2016
View PDFchevron_right
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam: INFORM 2012-2014
Wright W Nichols
Antimicrobial agents and chemotherapy, 2016
View PDFchevron_right
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis
Paul Beringer
Antimicrobial Agents and Chemotherapy
View PDFchevron_right
Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis
Tobias Welte
Journal of Antimicrobial Chemotherapy, 2003
View PDFchevron_right
Optimization of therapy against Pseudomonas aeruginosa with ceftazidime and meropenem using chemostats as model for infections
Constance Schultsz
FEMS Microbiology Letters, 2017
View PDFchevron_right
The primary pharmacology of ceftazidime/avibactam: resistancein vitro
Wright W Nichols
Journal of Antimicrobial Chemotherapy, 2023
View PDFchevron_right
Activity of Ceftolozane-Tazobactam Tested against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States During 2013 to 2015
Diego Llampa Mendoza
Antimicrobial agents and chemotherapy, 2017
View PDFchevron_right
Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae
Hjalmar Lagast
Antimicrobial Agents and Chemotherapy, 1983
View PDFchevron_right